Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR

Hohimer Wealth Management LLC purchased a new position in NovoCure Limited (NASDAQ:NVCR) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 76,600 shares of the medical equipment provider’s stock, valued at approximately $990,000. Hohimer Wealth Management LLC owned about 0.07% of NovoCure at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. SJS Investment Consulting Inc. bought a new stake in NovoCure during the 3rd quarter valued at about $41,000. Acadian Asset Management LLC bought a new position in shares of NovoCure in the first quarter worth approximately $87,000. Headlands Technologies LLC purchased a new stake in shares of NovoCure during the second quarter valued at approximately $88,000. AdvisorNet Financial Inc increased its position in shares of NovoCure by 137.7% during the third quarter. AdvisorNet Financial Inc now owns 9,700 shares of the medical equipment provider’s stock valued at $125,000 after acquiring an additional 5,619 shares in the last quarter. Finally, State of Tennessee Department of Treasury bought a new stake in shares of NovoCure during the second quarter valued at approximately $129,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

NovoCure Stock Performance

NVCR stock opened at $13.67 on Friday. The company has a market cap of $1.53 billion, a P/E ratio of -11.20 and a beta of 0.73. NovoCure Limited has a 1 year low of $9.82 and a 1 year high of $21.55. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. The stock’s fifty day moving average price is $12.73 and its 200-day moving average price is $12.65.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19. The company had revenue of $174.35 million during the quarter, compared to analysts’ expectations of $174.40 million. NovoCure had a negative return on equity of 38.82% and a negative net margin of 20.79%.NovoCure’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.61) earnings per share. On average, equities analysts forecast that NovoCure Limited will post -1.3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush reaffirmed a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a research report on Thursday, January 15th. HC Wainwright lifted their price objective on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NovoCure presently has an average rating of “Hold” and an average target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.